CompletedPhase 1 / Phase 2NCT05346380

Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download

This will be a prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy and pulmonary segmentectomy. The aims of the study are: 1\. To utilize NIR intraoperative imaging with the Olympus VE2 NIR Imaging System to: i. Characterize gastric conduit perfusion during esophagectomy and, ii. Identify segmental anatomy during sublobar pulmonary resection (segmentectomy) after intraoperative, intravenous delivery of low-dose 0.15 mg/kg of ICG.

Checked against the public recordLast updated Nov 26, 2025 · Source: ClinicalTrials.gov

StatusCompleted
PhasePhase 1 / Phase 2
U.S. locations1
SponsorMassachusetts General Hospital
01
Study overview

What this study is about

Purpose
Other
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Massachusetts General Hospital
Interventions being studied
Device: Olympus VE2 NIR Imaging System; Drug: Indocyanine green
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
03
Public criteria

Who may be able to participate

Inclusion Criteria: -Subject has a suspicious lung lesion for which a minimally invasive segmentectomy is planned -OR- sub-ject has an esophageal lesion for which an esophagectomy is planned - * Subject is 18 years of age or older * Subject is willing and able to provide informed consent Exclusion Criteria: * Subject is not eligible for surgical resection as determined by the treating physician * Subject has known or suspected allergy to Iodine, shellfish or intravenous contrast * Subject is not eligible or considered high risk for surgical resection as determined by pre-operative spirometry * Subject is female and of childbearing age who is currently pregnant or who is planning to become pregnant within the study * Subject is unable and unwilling to provide informed consent * Subject has liver disease or is taking drugs impact liver metabolism.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Massachusetts General HospitalBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 26, 2025. Always confirm current availability with the study team.

View original record ↗